Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short answer - yes my prescription V was swapped to generic V. I balked and they ordered V for me.
Great question -
It was originally off label, as I never had the >500 Tris, but I now fit the reduce-it indication.
Washington state - and not sure about identical cost, rather my copay was both $0, and I have the Vascepa $9 discount.
So just an anecdote - I went to refill my V prescription and they had refilled it with generic hikma. I obviously refused and asked to refill it with Vascepa. I asked if there was a cost difference to me and the rite aid/cvs pharmacist said no (I have an Aetna ppo plan). So, CVS swapped me without my knowledge, without there being a cost difference to me, and if I was an uneducated consumer, I may not have even known to ask for V instead of the generic....
Order just filled on Schwab 7k at .45
Don't worry, the MERCY uplist is coming soon.
Regarding the downside price action,
My guess is that there are some coordinated bear raids likely to help cover the short interest. That said,
I do think that we won't really be able to establish a strong floor price until we see the QE financial results in the 10k in August. Until they (even with the uplist), we should see much higher volatility based on the speculation of the revenue number, but once that is public, should be a much smaller range. While I agree the uplist and level 2 data will help quite a bit and cut down on some of the manipulation, the real revenue numbers will set the range. After that it should be normal catalysts in my opinion of which there should be plenty in this growth field.
It reminds me of the saying, if it looks like a duck and swims like a duck, then what is it? In this case, we know SOLI DOES NOT "look" like many pump and dumps/otc grey (e.g. we think it looks like a duck vs a turd burglar), but the financial results and swim test will PROVE that it's a duck, and should set the floor/channel as critical information.
Until we can observe this currently stationary duck actually "swimming" (or we could hope "flying) with the 10k, IMO we can see huge swings based on manipulation. That said, huge opportunity to get in before we see those results.
If you read the other great DD here on potential valuation, (especially smitter/daiello), but here is a way to think about it:
- Low-end valuation based on static best-known revenue from 2015 at TDOC similar valuation levels (.60)
- Med valuation based on expected growth ($2pps)
- Mid-high valulation (~$5pps)
- Upper end assuming 50M+ revenue (~$7p)
- Skys the limit (~$10pps in august, and growth to 20 on move to big boards)
So anyway, I think expect more bear raids until mid-august, but if shorts don't cover before then, pain is coming!
Late edit - also expanding on this though from a risk perspective based on the various upsides:
Let's say the risk is this stock is completely crap and worth 0.
Risk | Reward at current prices (anyone who got in, nice job!)
Low-end: Risk .65 | Reward .60 (basically 1-1 risk even)
Med: Risk .65 | Reward $2 (1 to 3 risk vs reward)
Mid-high Risk .65 | Reward $5 (1 to 8 risk vs reward)
Upper Risk .65 | Reward $7 (1 to 10 risk vs reward)
Given that many of the scenarios seem higher probability than the low-end, pretty good bet here..
I'm going to say 1.35.
Interesting question on the recession impact on Lipitor. Lipitor went off patent 2011, so it looks like there was an 8% drop and then a 9% drop, but already an deceleration that was already occurring.
https://www.statista.com/statistics/254341/pfizers-worldwide-viagra-revenues-since-2003/
Back to valuations for a sec -
https://www.fool.com/investing/2018/11/16/2-big-telemedicine-stocks-you-cant-buy-yet.aspx
Granted American Well has a bigger slice, but American well received $300M last year in additional investment (without mentioning an valuation of that 300M), but it shows the ballpark of the types of investments in these companies.
So here is the problem with fidelity... They use otcmarkets data - https://www.otcmarkets.com/stock/SOLI/overview and because it has a skull and crossbones it automatically blocks. I called them and they wouldn't trade it, so I ended buying via another broker.
I'm hoping the uplist will solve the skull/x-bones issues otherwise many fidelity traders can't participate...
Have any of the experts here thought of doing a seeking alpha article?
Yes I had a small market order open for like most of a day that didn't fill.
It filled relatively fast surprisingly - maybe 60 min - I'm on schwab and had previously had orders not fill for the entire day, so I put it at market.
Yeah that was me. I'm in for the long run.
Awesome - I knew someone had obviously built a better model.
I got in much later than most here (.51) - but seems like I should buy more based on what I'm reading!
So just to do a back of the envelope piss-poor and incorrect valuation -
TDOC = 419M Revenue, Market cap of 4.16B
SOLI = ?? Revenue, but let's say 20M-50M from careclix.
Forgetting expense side for a moment -
SOLI is ~5%-10% of the revenue with assumed similar costs, and you could argue a similar range for valuation, so logically ~200M-500M.
So based on the OS post lawsuit of approx 104M - you get a per share price of the $2-$5 range...
Is that where folks are getting the $1-$5/share on the uplist?
No, the correct word would have been apologists, unless LLC was referring to a religious use....
https://en.wikipedia.org/wiki/Apologetics
Sweet!
I've jumped in a bit - excited about an uplifting... quick question for those who have done the DD - so basically my take on the situation is one of a reverse merger, however the 10k specifically mentions some expected future dilution - what is your take on that?